Cargando…

A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm

BACKGROUND AND OBJECTIVES: Whether chemotherapy is needed in node-negative triple-negative breast cancer (TNBC) patients with tumor size less than 1 cm is still controversial. In our research, we constructed a novel risk-scoring system to identify the potential TNBC patients benefiting from adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yijun, Ma, Rulan, Chen, Heyan, Pu, Shengyu, Xie, Peiling, He, Jianjun, Zhang, Huimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260021/
https://www.ncbi.nlm.nih.gov/pubmed/35814418
http://dx.doi.org/10.3389/fonc.2022.788883
_version_ 1784741922910240768
author Li, Yijun
Ma, Rulan
Chen, Heyan
Pu, Shengyu
Xie, Peiling
He, Jianjun
Zhang, Huimin
author_facet Li, Yijun
Ma, Rulan
Chen, Heyan
Pu, Shengyu
Xie, Peiling
He, Jianjun
Zhang, Huimin
author_sort Li, Yijun
collection PubMed
description BACKGROUND AND OBJECTIVES: Whether chemotherapy is needed in node-negative triple-negative breast cancer (TNBC) patients with tumor size less than 1 cm is still controversial. In our research, we constructed a novel risk-scoring system to identify the potential TNBC patients benefiting from adjuvant chemotherapy in T1miN0M0, T1aN0M0, and T1bN0M0 stages. METHODS: Relevant data were extracted from the SEER database. We applied Kaplan-Meier curves and the Cox hazards model for survival analysis and developed a nomogram of overall survival. The X-tile software was used for risk stratification. The information of TNBC patients treated in the First Affiliated Hospital of Xi’an Jiaotong University was used for the application of the model. RESULTS: A total of 4266 patients who met the criteria of our study were included. T stage, age, race, surgery, and radiotherapy state were used to create the nomogram of overall survival. According to the total risk score, the patients were divided into high-risk (score g 73), median-risk (38 ≤ score < 73), and low-risk (score <38) groups. Chemotherapy can prolong the overall survival of patients in the median-risk and high-risk groups, while patients in the low-risk group can be exempted from chemotherapy. In addition, we also used the risk-scoring system in real-world patients as application and verification. CONCLUSION: We constructed a novel risk-scoring system that can be used as a chemotherapy decision-making tool for node-negative TNBC patients with tumor size less than 1 cm. Tumor size should not be the only criterion for chemotherapy treatment decision-making.
format Online
Article
Text
id pubmed-9260021
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92600212022-07-08 A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm Li, Yijun Ma, Rulan Chen, Heyan Pu, Shengyu Xie, Peiling He, Jianjun Zhang, Huimin Front Oncol Oncology BACKGROUND AND OBJECTIVES: Whether chemotherapy is needed in node-negative triple-negative breast cancer (TNBC) patients with tumor size less than 1 cm is still controversial. In our research, we constructed a novel risk-scoring system to identify the potential TNBC patients benefiting from adjuvant chemotherapy in T1miN0M0, T1aN0M0, and T1bN0M0 stages. METHODS: Relevant data were extracted from the SEER database. We applied Kaplan-Meier curves and the Cox hazards model for survival analysis and developed a nomogram of overall survival. The X-tile software was used for risk stratification. The information of TNBC patients treated in the First Affiliated Hospital of Xi’an Jiaotong University was used for the application of the model. RESULTS: A total of 4266 patients who met the criteria of our study were included. T stage, age, race, surgery, and radiotherapy state were used to create the nomogram of overall survival. According to the total risk score, the patients were divided into high-risk (score g 73), median-risk (38 ≤ score < 73), and low-risk (score <38) groups. Chemotherapy can prolong the overall survival of patients in the median-risk and high-risk groups, while patients in the low-risk group can be exempted from chemotherapy. In addition, we also used the risk-scoring system in real-world patients as application and verification. CONCLUSION: We constructed a novel risk-scoring system that can be used as a chemotherapy decision-making tool for node-negative TNBC patients with tumor size less than 1 cm. Tumor size should not be the only criterion for chemotherapy treatment decision-making. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9260021/ /pubmed/35814418 http://dx.doi.org/10.3389/fonc.2022.788883 Text en Copyright © 2022 Li, Ma, Chen, Pu, Xie, He and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yijun
Ma, Rulan
Chen, Heyan
Pu, Shengyu
Xie, Peiling
He, Jianjun
Zhang, Huimin
A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
title A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
title_full A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
title_fullStr A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
title_full_unstemmed A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
title_short A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
title_sort novel risk-scoring system to identify the potential population benefiting from adjuvant chemotherapy for node-negative tnbc patients with tumor size less than 1 cm
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260021/
https://www.ncbi.nlm.nih.gov/pubmed/35814418
http://dx.doi.org/10.3389/fonc.2022.788883
work_keys_str_mv AT liyijun anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT marulan anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT chenheyan anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT pushengyu anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT xiepeiling anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT hejianjun anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT zhanghuimin anovelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT liyijun novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT marulan novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT chenheyan novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT pushengyu novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT xiepeiling novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT hejianjun novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm
AT zhanghuimin novelriskscoringsystemtoidentifythepotentialpopulationbenefitingfromadjuvantchemotherapyfornodenegativetnbcpatientswithtumorsizelessthan1cm